WJA
GILD icon

Willis Johnson & Associates’s Gilead Sciences GILD Stock Holding History

Willis Johnson & Associates’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,797
Closed -$201K – 171
2025
Q1 		$201K Buy
+1,797
New +$185K 0.02% 159

Other funds holding GILD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Willis Johnson & Associates's GILD Position: Q2 2025 in Review

Willis Johnson & Associates sold out of Gilead Sciences (GILD) in Q2 2025, closing a stake of 1,797 shares — an estimated $201K sold.

Willis Johnson & Associates first reported a position in GILD in Q1 2025 and held it in 1 quarter. The position peaked at $201K in Q1 2025. 2,023 funds tracked by Wall St. Rank hold GILD as of Q2 2025.

  • Willis Johnson & Associates reported no remaining Gilead Sciences position as of Q2 2025 after selling out during the quarter.
  • Willis Johnson & Associates sold 1,797 Gilead Sciences shares in Q2 2025, an estimated $201K.
  • Willis Johnson & Associates first reported a position in Gilead Sciences in Q1 2025 and held it in 1 quarter.
  • Willis Johnson & Associates's Gilead Sciences position peaked at $201K in Q1 2025.
  • 2,023 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2025.

Based on Willis Johnson & Associates's 13F filing for Q2 2025, filed 13 Aug 2025.